Antonio Braga

Dr. Antonio Braga

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2019 in World Journal of Clinical Oncology
Verified
Journal Article
Open access
ABAntonio Braga
Antonio Braga
PMPaulo Mora
Paulo Mora
AMAndréia Cristina de Melo
Andréia Cristina de Melo
ANAngélica Nogueira-Rodrigues
Angélica Nogueira-Rodrigues
JAJoffre Amim-Junior
Joffre Amim-Junior
MSMichael J Seckl
Michael J Seckl
Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide

1 April 2017 in Gynecologic Oncology
Verified
Journal Article
Closed access
LLLawrence Hsu Lin
Lawrence Hsu Lin
IMIzildinha Maestá
Izildinha Maestá
ABAntonio Braga
Antonio Braga
SSSue Yazaki Sun
Sue Yazaki Sun
KFKoji Fushida
Koji Fushida
RBRoss Berkowitz
Ross Berkowitz

1 July 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
SSSue Yazaki Sun
Sue Yazaki Sun
AMAlexander Melamed
Alexander Melamed
DGDonald P. Goldstein
Donald P. Goldstein
MBMarilyn R. Bernstein
Marilyn R. Bernstein
NHNeil S. Horowitz
Neil S. Horowitz
RBRoss Berkowitz
Ross Berkowitz

1 August 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
FFFernanda Freitas
Fernanda Freitas
ABAntonio Braga
Antonio Braga
MVMauricio Viggiano
Mauricio Viggiano
LVLuis Guillermo Coca Velarde
Luis Guillermo Coca Velarde
IMIzildinha Maestá
Izildinha Maestá
RBRoss S. Berkowitz
Ross S. Berkowitz

1 January 2015 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
ABAndressa Biscaro
Andressa Biscaro
ABAntonio Braga
Antonio Braga
RBRoss Stuart Berkowitz
Ross Stuart Berkowitz
Gestational trophoblastic neoplasia (GTN) is the term to describe a set of malignant placental diseases, including invasive mole, choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor. Both invasive mole and choriocarcinoma respond well to chemotherapy, and cure rates are greater than 90%. Since the advent of chemotherapy, low-risk GTN has been treated with a single agent, usually methotrexate or actinomycin D. Cases of high-risk GTN, however, should be treated with multiagent chemotherapy, and the regimen usually selected is EMA-CO, which combines etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine. This study reviews the literature about GTN to discuss current knowledge about its diagnosis and treatment.

1 August 2016 in Radiologia Brasileira
Verified
Journal Article
Open access
PDF file
LLLana de Lourdes Aguiar Lima
Lana de Lourdes Aguiar Lima
RPRaphael Câmara Medeiros Parente
Raphael Câmara Medeiros Parente
IMIzildinha Maestá
Izildinha Maestá
JJJoffre Amim Junior
Joffre Amim Junior
JFJorge Fonte de Rezende Filho
Jorge Fonte de Rezende Filho
ABAntonio Braga
Antonio Braga
Gestational trophoblastic disease is an abnormality of pregnancy that encompasses a group of diseases that differ from each other in their propensity for regression, invasion, metastasis, and recurrence. In the past, it was common for patients with molar pregnancy to present with marked symptoms: copious bleeding; theca lutein cysts; uterus larger than appropriate for gestational age; early preeclampsia; hyperemesis gravidarum; and hyperthyroidism. Currently, with early diagnosis made by ultrasound, most patients are diagnosed while the disease is still in the asymptomatic phase. In cases of progression to trophoblastic neoplasia, staging-typically with Doppler flow studies of the pelvis and chest X-ray, although occasionally with computed tomography or magnetic resonance imaging-is critical to the choice of an appropriate antineoplastic therapy regimen. Because it is an unusual and serious disease that affects women of reproductive age, as well as because its appropriate treatment results in high cure rates, it is crucial that radiologists be familiar with gestational trophoblastic disease, in order to facilitate its early diagnosis and to ensure appropriate follow-up imaging.